SCHEMBL22346136

SCHEMBL22346136

CC[C@H](C)[C@@H](C(=O)OCc1ccccc1)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.46
POLB P06746 1/20 0.43
CTSL P07711 2/20 0.43
CTSB P07858 2/20 0.43
CTSS P25774 2/20 0.43
CTSK P43235 2/20 0.43
ABCB1 P08183 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 2/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22346137 1.00 SYK (0.46) SYKPOLBCTSLCTSBCTSS
SCHEMBL14502788 0.95 SYK (0.43) SYKPOLBCTSLCTSBCTSS
SCHEMBL21447757 0.92 SYK (0.43) SYKPOLBCTSLCTSBCTSS
SCHEMBL18256457 0.92 SYK (0.43) SYKPOLBCTSLCTSBCTSS
SCHEMBL18248084 0.92 SYK (0.43) SYKPOLBCTSLCTSBCTSS
SCHEMBL25203184 0.89 POLB (0.45) SYKPOLBCTSLCTSBCTSS
SCHEMBL19393967 0.89 POLB (0.45) SYKPOLBCTSLCTSBCTSS
SCHEMBL22346460 0.86 SYK (0.46) SYKPOLBCTSLCTSBCTSS
SCHEMBL30307663 0.84 POLB (0.47) SYKPOLBABCB1L3MBTL1ALDH1A1
SCHEMBL2499502 0.84 POLB (0.47) SYKPOLBABCB1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230132386-A9 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. 2023-04-27 US disclosed
US-20230132386-A9 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. 2023-04-27 US disclosed
US-20230132386-A9 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. 2023-04-27 US disclosed
US-20220135593-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC (US) 2022-05-05 US disclosed
US-20220135593-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC (US) 2022-05-05 US disclosed
EP-3924354-A1 GRANZYME B DIRECTED IMAGING AND THERAPY Cytosite Biopharma Inc. (US) 2021-12-22 EP disclosed
WO-2020167989-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. (US) 2020-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230132386-A9 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB SYK 1657/4885POLB 849/4885CTSL 87/4885
US-20220135593-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB SYK 1657/4885POLB 849/4885CTSL 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.